Joshua S. Boger - 11 Jun 2026 Form 4 Insider Report for CervoMed Inc. (CRVO)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: CRVO
Reported as of: 11 Jun 2026
Net transaction value: +$3,000,000
SEC form: 4
Accepted by SEC: 15 Jun 2026, 17:37:36 UTC
Prior SEC filing: 10 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ William R. Elder, attorney-in-fact for the Reporting Person

Key filing fact

Joshua S. Boger filed Form 4 for CervoMed Inc. (CRVO) on 15 Jun 2026.

Key facts

This page summarizes Joshua S. Boger's Form 4 filing for CervoMed Inc. (CRVO).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 15 Jun 2026, 17:37.

Change

Previous filing in this sequence was filed on 10 Jun 2026.
Current net transaction value: +$3,000,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001197023 Primary reporting owner

BOGER JOSHUA S

Relationship: Director, 10%+ Owner
Address: 20 PARK PLAZA, SUITE 424, BOSTON
Signature: /s/ William R. Elder, attorney-in-fact for the Reporting Person
Signature date: 15 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRVO transaction

Common Stock

Purchase

Transaction value: $3,000,000
Shares: +955,414
Change %: +114%
Price: $3.14
Shares after: 1,795,865
Date: 11 Jun 2026
Ownership: By Trusts
Footnotes: F1, F2

CRVO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 216,817
Date: 11 Jun 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRVO transaction Derivative

Series B Warrants

Purchase

Transaction value
Shares: +955,414
Change %
Price
Shares after: 955,414
Date: 11 Jun 2026
Ownership: By Trust
Underlying class: Common Stock
Underlying amount: 955,414
Exercise price: $3.32
Footnotes: F1, F3, F5, F6

CRVO transaction Derivative

Series C Warrants

Purchase

Transaction value
Shares: +955,414
Change %
Price
Shares after: 955,414
Date: 11 Jun 2026
Ownership: By Trust
Underlying class: Common Stock
Underlying amount: 955,414
Exercise price: $3.14
Footnotes: F1, F4, F5, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

On June 11, 2026, the Issuer completed a private placement (the "Private Placement") pursuant to a securities purchase agreement, dated June 9, 2026 (the "Purchase Agreement"), with the Joshua S. Boger 2021 Trust DTD 12/09/2021, of which the Reporting Person serves as the sole trustee (the "JSB 2021 Trust"), and certain accredited investors named therein. Pursuant to the Purchase Agreement, the JSB 2021 Trust purchased an aggregate of 955,414 units (the "Units"), each Unit comprised of (i) one share of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) one Series B warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series B Warrant"), and (iii) one Series C warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series C Warrant") for a purchase price of $3.14 per Unit.

Footnote F2

After giving effect to all transactions described herein, consists of (i) 1,600,117 shares of the Issuer's common stock held by the JSB 2021 Trust and (ii) 195,748 shares of the Issuer's common stock held by The Amy S. Boger 2021 Trust (the "ASB 2021 Trust"). The Reporting Person serves as the sole trustee of each of the JSB 2021 Trust and the ASB 2021 Trust. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Footnote F3

The Series B Warrants have an exercise price equal to $3.32 per share of Common Stock or $3.319 per pre-funded warrant, are exercisable immediately, and will expire five years from the issuance date of the Series B Warrant.

Footnote F4

The Series C Warrants have an exercise price equal to $3.14 per share of Common Stock or $3.139 per pre-funded warrant, are exercisable immediately, and will expire one year from the issuance date of the Series C Warrant.

Footnote F5

Under the terms of the Series B Warrants and the Series C Warrants, the Issuer may not effect the exercise of any portion thereof, and the JSB 2021 Trust will not have the right to exercise any portion thereof, which, upon giving effect to such exercise, would cause the JSB 2021 Trust (together with its affiliates) to own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. To the extent that exercise of the Series B Warrants or Series C Warrants will result in the JSB 2021 Trust (together with its affiliates) beneficially owning shares of Common Stock above such ownership limitations, the JSB 2021 Trust may exercise its Series B Warrants or Series C Warrants for pre-funded warrants to purchase shares of Common Stock, which pre-funded warrants will include a substantially similar maximum ownership limitation.

Footnote F6

The Series B Warrants and Series C Warrants are owned by the JSB 2021 Trust.